Published in Neurology on April 26, 2013
Molecular interaction between the chaperone Hsc70 and the N-terminal flank of huntingtin exon 1 modulates aggregation. J Biol Chem (2014) 0.86
Induced Pluripotent Stem Cells in Huntington's Disease Research: Progress and Opportunity. J Huntingtons Dis (2016) 0.85
Prospects for neuroprotective therapies in prodromal Huntington's disease. Mov Disord (2014) 0.80
Factors influencing the clinical expression of intermediate CAG repeat length mutations of the Huntington's disease gene. J Neurol (2014) 0.77
What do we know about Late Onset Huntington's Disease? J Huntingtons Dis (2017) 0.77
Neurodegenerative disease: 'fifty shades of grey' in the Huntington disease gene. Nat Rev Neurol (2013) 0.76
Huntington disease: How many repeats does it take? Neurology (2013) 0.76
Redefining the genetic risk for Huntington disease. Neurology (2013) 0.76
Epigenetics of Huntington's disease. J Neurol (2013) 0.75
Dominant-Negative Effects of Adult-Onset Huntingtin Mutations Alter the Division of Human Embryonic Stem Cells-Derived Neural Cells. PLoS One (2016) 0.75
Clinical utility gene card for: Huntington's disease. Eur J Hum Genet (2013) 0.75
CAG repeat size in Huntingtin alleles is associated with cancer prognosis. Eur J Hum Genet (2016) 0.75
Unified Huntington's Disease Rating Scale: reliability and consistency. Huntington Study Group. Mov Disord (1996) 8.02
Trinucleotide repeat length instability and age of onset in Huntington's disease. Nat Genet (1993) 6.53
The fragile-X premutation: a maturing perspective. Am J Hum Genet (2004) 3.89
A new polymerase chain reaction (PCR) assay for the trinucleotide repeat that is unstable and expanded on Huntington's disease chromosomes. Mol Cell Probes (1993) 3.76
Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. Proc Natl Acad Sci U S A (2004) 3.73
Phenotypic characterization of individuals with 30-40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36-39 repeats. Am J Hum Genet (1996) 2.88
Psychiatric symptoms in Huntington's disease before diagnosis: the predict-HD study. Biol Psychiatry (2007) 2.71
Neuropsychiatric aspects of Huntington's disease. J Neurol Neurosurg Psychiatry (2001) 2.04
CGG repeat in the FMR1 gene: size matters. Clin Genet (2011) 1.68
The association of affective disorder with Huntington's disease in a case series and in families. Psychol Med (1983) 1.65
Measurement of mutational flow implies both a high new-mutation rate for Huntington disease and substantial underascertainment of late-onset cases. Am J Hum Genet (2001) 1.39
Predictive testing for Huntington disease: interpretation and significance of intermediate alleles. Clin Genet (2006) 1.29
Factors differentiating dropouts from completers in a longitudinal, multicenter clinical trial. Nurs Res (2000) 1.28
Specific psychiatric manifestations among preclinical Huntington disease mutation carriers. Arch Neurol (2007) 1.25
At risk for Huntington disease: The PHAROS (Prospective Huntington At Risk Observational Study) cohort enrolled. Arch Neurol (2006) 1.25
New problems in testing for Huntington's disease: the issue of intermediate and reduced penetrance alleles. J Med Genet (2001) 1.19
Technical standards and guidelines for Huntington disease testing. Genet Med (2004) 1.17
Reduced penetrance alleles for Huntington's disease: a multi-centre direct observational study. J Med Genet (2007) 1.07
Premature ovarian failure among fragile X premutation carriers: parent-of-origin effect? Am J Hum Genet (2000) 1.03
Late-onset Huntington disease with intermediate CAG repeats: true or false? J Neurol Neurosurg Psychiatry (2010) 0.99
Exploring the correlates of intermediate CAG repeats in Huntington disease. Postgrad Med (2011) 0.98
Effect of CAG repeat length on psychiatric disorders in Huntington's disease. J Psychiatr Res (2007) 0.94
Correlates of apathy in Huntington's disease. J Neuropsychiatry Clin Neurosci (2010) 0.86
Treatment of Apathy in Huntington's Disease and Other Movement Disorders. Curr Treat Options Neurol (2011) 0.85
Suicidality in Huntington's disease. J Affect Disord (2011) 0.85
Intermediate CAG Repeats in Huntington's Disease: Analysis of COHORT. Tremor Other Hyperkinet Mov (N Y) (2012) 0.84
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord (2008) 9.52
A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med (2009) 5.81
Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science (2007) 5.49
Levodopa and the progression of Parkinson's disease. N Engl J Med (2004) 5.44
Phenomenology and classification of dystonia: a consensus update. Mov Disord (2013) 4.98
Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science (2002) 4.72
Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol (2002) 4.60
Regional and cellular gene expression changes in human Huntington's disease brain. Hum Mol Genet (2006) 3.91
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord (2007) 3.86
Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol (2010) 3.84
Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. Proc Natl Acad Sci U S A (2004) 3.73
Preparing for preventive clinical trials: the Predict-HD study. Arch Neurol (2006) 3.57
DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain (2010) 3.57
PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease. Sci Transl Med (2010) 3.48
Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. Am J Hum Genet (2003) 3.39
Age at onset in two common neurodegenerative diseases is genetically controlled. Am J Hum Genet (2002) 2.90
Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol (2011) 2.84
Movement disorders in cerebrovascular disease. Lancet Neurol (2013) 2.81
Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol (2008) 2.79
Patient selection and assessment recommendations for deep brain stimulation in Tourette syndrome. Mov Disord (2006) 2.72
Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol (2010) 2.67
Subthalamic deep brain stimulation with a constant-current device in Parkinson's disease: an open-label randomised controlled trial. Lancet Neurol (2012) 2.50
Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol (2009) 2.46
CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol (2008) 2.34
Autopsy-proven Huntington's disease with 29 trinucleotide repeats. Mov Disord (2007) 2.34
The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease. Brain (2008) 2.34
Mutations in NR4A2 associated with familial Parkinson disease. Nat Genet (2002) 2.27
Camptocormia: pathogenesis, classification, and response to therapy. Neurology (2005) 2.26
Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease. Mov Disord (2012) 2.18
Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain. Hum Mol Genet (2002) 2.17
Beyond disgust: impaired recognition of negative emotions prior to diagnosis in Huntington's disease. Brain (2007) 2.17
Mutations in the gene PRRT2 cause paroxysmal kinesigenic dyskinesia with infantile convulsions. Cell Rep (2011) 2.17
The many faces of hemifacial spasm: differential diagnosis of unilateral facial spasms. Mov Disord (2011) 2.16
Neurocognitive signs in prodromal Huntington disease. Neuropsychology (2011) 2.14
Are Parkinson disease patients protected from some but not all cancers? Neurology (2007) 2.12
Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol (2004) 2.02
Long-term evaluation of deep brain stimulation of the thalamus. J Neurosurg (2006) 2.02
Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis (2006) 2.00
Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease. Hum Mol Genet (2003) 1.98
Head injury and Parkinson's disease risk in twins. Ann Neurol (2006) 1.93
Genetics of essential tremor. Brain (2007) 1.89
A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo. Proc Natl Acad Sci U S A (2005) 1.88
Update on blepharospasm: report from the BEBRF International Workshop. Neurology (2008) 1.87
Contemporary assessment and pharmacotherapy of Tourette syndrome. NeuroRx (2006) 1.82
Exploring the relationship between essential tremor and Parkinson's disease. Parkinsonism Relat Disord (2006) 1.82
Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions. Mov Disord (2008) 1.78
Respiratory problems in neurologic movement disorders. Parkinsonism Relat Disord (2010) 1.76
Impulse control disorders and pathological gambling in patients with Parkinson disease. Neurologist (2008) 1.74
Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases. Proc Natl Acad Sci U S A (2006) 1.73
Relationship between neuropsychological outcome and DBS surgical trajectory and electrode location. J Neurol Sci (2009) 1.73
CSF Aβ(42) and tau in Parkinson's disease with cognitive impairment. Mov Disord (2010) 1.71
Partitioning the heritability of Tourette syndrome and obsessive compulsive disorder reveals differences in genetic architecture. PLoS Genet (2013) 1.68
A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol (2011) 1.68
Premutation alleles associated with Parkinson disease and essential tremor. JAMA (2004) 1.65
Small interfering RNA targeting the PINK1 induces apoptosis in dopaminergic cells SH-SY5Y. Biochem Biophys Res Commun (2005) 1.64
Clinical gait and balance scale (GABS): validation and utilization. J Neurol Sci (2004) 1.62
Drug-induced psychosis in Parkinson disease: phenomenology and correlations among psychosis rating instruments. Clin Neuropharmacol (2005) 1.61
Concept of assessing nanoparticle hazards considering nanoparticle dosemetric and chemical/biological response metrics. J Toxicol Environ Health A (2010) 1.61
Migraine headache in patients with Tourette syndrome. Arch Neurol (2003) 1.61
Impaired olfaction and other prodromal features in the Parkinson At-Risk Syndrome Study. Mov Disord (2012) 1.60
Minocycline in Huntington's disease: a pilot study. Mov Disord (2004) 1.59
Multiple LRRK2 variants modulate risk of Parkinson disease: a Chinese multicenter study. Hum Mutat (2010) 1.57
Environmental lead exposure during early childhood. J Pediatr (2002) 1.56
Occupation and risk of parkinsonism: a multicenter case-control study. Arch Neurol (2009) 1.56
Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord (2008) 1.56
Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord (2005) 1.54
Verbal episodic memory declines prior to diagnosis in Huntington's disease. Neuropsychologia (2007) 1.54
Striatal deformities of the hand and foot in Parkinson's disease. Lancet Neurol (2005) 1.54
Randomized clinical trial of pacifier use and bottle-feeding or cupfeeding and their effect on breastfeeding. Pediatrics (2003) 1.53
Minocycline and other tetracycline derivatives: a neuroprotective strategy in Parkinson's disease and Huntington's disease. Clin Neuropharmacol (2003) 1.53
Disease progression and pharmacodynamics in Parkinson disease - evidence for functional protection with levodopa and other treatments. J Pharmacokinet Pharmacodyn (2006) 1.53
Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline. Mov Disord (2006) 1.53
Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies. Arch Gen Psychiatry (2003) 1.53
Camptocormia, head drop and other bent spine syndromes: heterogeneous etiology and pathogenesis of Parkinsonian deformities. Mov Disord (2010) 1.52
Increasing access to specialty care: a pilot, randomized controlled trial of telemedicine for Parkinson's disease. Mov Disord (2010) 1.50
Test-retest reliability of the unified Parkinson's disease rating scale in patients with early Parkinson's disease: results from a multicenter clinical trial. Mov Disord (2002) 1.48
Secondary tics and tourettism. Rev Bras Psiquiatr (2005) 1.47
Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci (2011) 1.46
Toward more efficient clinical trials for amyotrophic lateral sclerosis. Amyotroph Lateral Scler (2010) 1.45
Neuroprotection of rapamycin in lactacystin-induced neurodegeneration via autophagy enhancement. Neurobiol Dis (2008) 1.43
Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease. Neurosci Lett (2010) 1.42
Caffeine consumption and risk of dyskinesia in CALM-PD. Mov Disord (2013) 1.42